Donald E. Nickelson joined the Board of Directors as Chairman in May 2008. Mr. Nickelson is currently the Vice-Chairman and Director of Harbour Group Industries Inc., a leveraged buy-out firm. He also serves as chairman of the board of advisors for Celtic Therapeutics, a director of Adolor Corporation, First Advantage Corporation and the Advisory Board of Celtic Pharmaceutical Holdings, L.P., as well as serving on the board of several private companies.

Previously, Mr. Nickelson was President of PaineWebber Group, an investment banking and brokerage firm, and acted as Lead Trustee of the Mainstay Mutual Funds Group. He served as the Chairman of the Board of Omniquip International, Inc., Greenfield Industries, Vie Financial Group, and Flair Corporation. As a Director, Mr. Nickelson served on the boards for W. P. Carey & Co., LLC, Royalty Pharma AG, Allied Healthcare Products, DT Industries, as well as Selectide Corporation and Sugen, Inc., two biotech companies. In addition, he served as Chairman of the Pacific Stock Exchange and Director of the Chicago Board Options Exchange.

James Grau is President and CEO of Cross Match and has more than 30 years of experience in sales and marketing, manufacturing and operational planning, including 13 years in a chief executive management capacity. Previously, Mr. Grau was Group President, Microwave Components and Subsystems for Smiths Group PLC, a leader in the practical application of advanced technologies for the threat and contraband detection, medical devices, energy and communications markets worldwide. While at Smiths, he established and managed the Microwave Components and Subsystems Group, consisting of four separate business operations, leading it to generate some of the highest net profit margins within Smiths. Mr. Grau also has served as CEO for LEA International, Veridien Corporation and Nationwide Industries. Prior to this, he held various management and sales and marketing positions in Kaepa, Inc., Marketing Corporate of America, Borden Company and the Drackett Company (a division of Bristol Myers). Mr. Grau earned his Bachelor of Business Administration from the University of Cincinnati.

Stephen Evans-Freke is Co-Founder and Managing General Partner of Celtic Therapeutics and Co-Founder and Managing Principal of Celtic Pharma, both global private equity funds focused on the pharmaceutical industry.

Mr. Evans-Freke has been associated with the biotechnology industry for over 24 years, as an investment banker, asset manager, entrepreneur, company CEO, and venture capitalist. During the 1980s, he was lead investment banker to Genentech, AMGEN, Centocor, and a number of other leading biotech companies, structured and placed over $500 million of highly successful R&D partnership financing, and served on the Development Boards of these companies. During this period, Mr. Evans-Freke was President of PaineWebber Development Corporation and later a member of PaineWebber Inc.'s Board of Directors.

In 1990 Mr. Evans-Freke left Wall St. and founded Selectide Corporation, one of the first combinatorial chemistry companies, for which he served as Chairman until its sale to Heochst in 1994. In 1991, Mr. Evans-Freke founded SUGEN, a drug discovery company focused on small molecule kinase and phosphatase inhibitors; he served as SUGEN Chairman and Chief Executive Officer through its IPO with Morgan Stanley in 1995 and until its sale to Pharmacia for $720 million in 1999. During this time, Mr. Evans-Freke was also a co-founder of Fibrogen, Inc. and Royalty Pharma AG.

Subsequently, Mr. Evans-Freke served as an advisor to Pharmacia CEO Fred Hassan until 2001 and devoted himself to his personal venture investments until the founding of Celtic Pharma in 2004. He currently serves on the Boards of Cibus Genetics (Chairman), and International BioScience Managers, Ltd. Mr. Evans-Freke also serves on the 800-Year Anniversary Appeal Board of Cambridge University, from which he holds a degree in Law; the Cambridge Stem Cell Board; the Board of Governors of the U.S. Priory of the Order of St. John; and the Board of the Christopher and Dana Reeve Foundation. Mr. Evans-Freke is a citizen of the U.K. and Ireland and has been a resident of the U.S. for 28 years.

John Langston has served as a Director since April 2008. Since December 2000 he has served as a Director of Smiths Group plc. A Chartered Accountant, Mr. Langston was appointed Finance Director of Smiths Group plc in September 2006. Mr. Langston has held various senior management positions within Smiths Group, including Group Managing Director -- Specialty Engineering, Group Managing Director – Detection and head of Sealing Solutions.

Mr. Langston had been a director of TI Group plc since October 1998. He joined TI Group in 1993, becoming Chief Executive of Bundy Automotive in 1996 and Chief Executive of TI Specialty Polymer Products in 1998. He formerly worked for Lucas Industries.

Stephen Phipson has served as a Director since April 2008. Since August 2004 he has served as Group Managing Director of Smiths Detection. Mr. Phipson was previously Managing Director of Smiths Interconnect, the hi-tech communications arm of Smiths’ Specialty Engineering division. He joined Smiths in 1997 as Managing Director of Smiths Interconnect, a global leader in the supply of application specific high reliability electronic components and subsystems, with operations in Europe, the USA, Central America, Japan and China.

With an MSc in Operations Management, Mr. Phipson has held several senior roles in the electronics industry including positions at Philips and Plessey. Prior to Smiths, he was Managing Director of Radiall UK, a global supplier of microwave components and systems.

Edward J. Robinson became a director in May 2008 and currently serves as Chairman of the Audit Committee. Mr. Robinson, a certified public accountant, was Chief Operating Officer of Meditrust Operating Company, a healthcare REIT, from 1997 to 1998. Previously, Mr. Robinson was President and Chief Operating Officer of Avon Products, Inc., a beauty and related products company, from 1993 to 1997 and Executive Vice President and Chief Financial Officer from 1989 to 1992. Prior thereto, he was Executive Vice President and Chief Financial Officer of RJR Nabisco and held various financial positions with RJR Nabisco, a consumer products company, and its predecessor companies, Standard Brands and Nabisco Brands.

Mr. Robinson serves on the Advisory Board of W.R. Capital Management, L.P., is the Chairman of the Audit Committee of Bentley Pharmaceuticals, Inc., a specialty pharmaceutical company, and is a member of the audit committee for Medical Staffing Network Holdings, Inc. Mr. Robinson is a Certified Public Accountant licensed by the State of New York. Mr. Robinson has been retired since 1998.

Ryan L. Roney has served as a Director since April 2009. Mr. Roney is the General Counsel of Smiths Detection, a subsidiary of Smiths Group. He first joined Smiths in October 2000 as Corporate Counsel for the Aerospace division where he held various legal positions. Mr. Roney also served in various legal capacities at Smiths Group, eventually moving to the Detection business in 2004. Prior to joining Smiths, he was with White & Case in Los Angeles and clerked for the Honorable Robert D. Potter, United States District Court Judge.

Jerry Zionic has served as director since February 2009. He held several positions within Lockheed Martin including Vice President, New Business Ventures and Vice President for Advanced Programs. Mr. Zionic managed the integration of a U.K. acquisition, INSYS, into Lockheed Martin, while serving as the interim Managing Director. Prior to his move to the U.K., Mr. Zionic was President at Lockheed Martin Simulation, Training and Support--a $1B operating element of the corporation's Electronic Systems Business Area. While at Martin Marietta Corporation (MMC) in the 1990s, Mr. Zionic was responsible for new business pursuits and identified the criminal justice market as a focus for corporate growth. He spearheaded MMC's involvement in the national Integrated Automated Fingerprint Identification System (IAFIS), an automated fingerprint identification and criminal history system maintained by the Federal Bureau of Investigation (FBI). Once completed, Mr. Zionic leveraged the success to secure MMC's management of the FBI's Card Scanning Services (CCS) program.

Before joining the private sector, Mr. Zionic completed more than 11 years of active duty with the United States Air Force (USAF). After his tenure with USAF Special Projects, Mr. Zionic held a civil service position at the Pentagon in the Office of the Assistant Secretary of Defense for Intelligence. Mr. Zionic is a graduate of the United States Air Force Academy. He earned two Masters of Science degrees for Aerospace Engineering and Information/Control Engineering from the University of Michigan.